? ?? The team at Spanios is thrilled to announce our partnership with ACCELERATED BIOSCIENCES CORP. to drive innovation in solid tumor cancer therapeutics. The partnership combines Spanios’s proprietary COMPASS platforms and patient-derived tumoroid models with Accel Bio’s hTSC platform to advance therapeutic design across solid tumor cancers. This powerful collaboration aims to accelerate the development of novel, potentially life-saving treatments for patients battling solid tumors like ovarian and colorectal cancers. Read more about our partnership at: #oncology #cancerresearch #biotechnology
关于我们
We harness the powerful capabilities of Patient Derived Tumoroids (PDTs) to accelerate the drug development process for solid tumor cancers. Our platform uniquely creates stable tumor models that are biobanked for rapid deployment and enables reproducible studies. We maintain an intact and functional tumor microenvironment (TME) for therapeutic discoverers and developers whose studies require robust and faithful preclinical research models. Our unique 3D tumor models enable the recapitulation of patient-specific tumor-immune interactions to fast-track the search for novel cures and bring hope to millions of patients. Tumoroids are the perfectly optimized human tool for performing: biomarker discovery drug selection & ratios for more informed treatment decisions assessment of combination therapies drug rescue & repurposing search for predictive signatures of drug failure, toxicity and response derisking clinical trials testing within the platform to facilitate precision cancer immunotherapy
- 网站
-
www.spanioslab.com
Spanios的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Houston，Texas
- 类型
- 私人持股
地点
-
主要
获取路线
2450 Holcombe Blvd
US，Texas，Houston，77021
Spanios员工
动态
-
Thank you Portal Innovations, LLC for your warm welcome. We look forward to working towards our mutual growth and success!
Please welcome our latest member company, Spanios, to Portal Houston - Helix Park! Spanios was launched with the mission to accelerate the development of targeted therapeutics in cancer by utilizing tumor microenvironment (TME) based robust human on human cancer model system. They addressed the unmet need of such model systems by building the modality and indication agnostic Custom Organoid Modelling Platform for Accurate & Speedy Solutions (COMPASS), which encompasses different levels of TME ranging from functional immunocompetence to different levels of physiological oxygenation. In their hub-and-spoke business model in addition to providing fee for service for their client, they have two co-development and one in-house therapeutic in the pipeline. They are currently doing confirmatory preclinical studies in pancreatic, ovarian and stomach cancers utilizing our proprietary COMPASS tumoroid platform. Welcome to Portal! Learn more about what Spanios is doing by visiting their site here: https://lnkd.in/gge8jdtC
-
-
To new beginnings, renewed energy and fresh prospectives.
Houston, Portal has launched ?? What an exciting evening filled with excellent lineup of speakers, great food and drinks, DJ, and yes the live streaming on that ginormous screen!! Congratulations to the entire Portal Innovations, LLC Houston team Monique (Pierre) Knighten Joanna Krakowiak, PhD, Tim and Zach you guys definitely know how to make your members feel like family, and y’all know how to throw Texas sized fun paaarrrtyyy!! Bhuvanesh Dave, Harrison Seidner, PhD, Damieanus Ochola, Dean Remy, Huckie Del Mundo, MD, MBE, Spanios
-
-
-
-
-
+5
-
-
Spanios转发了
We’re excited to share our case study for Spanios! Our concept aimed to create the feeling of looking inside a well filled with cells and tumoroids. This work highlights key physiological mechanisms, contributing to ethical research in immuno-oncology. In addition to developing fully animated models of tumoroids, we also designed artwork for their exhibition booth at a conference in San Diego. Check out the full case study for more details, and reach out if you need our expert assistance on your project! https://lnkd.in/gfrYX9Yk #ImmunoOncology #Tumoroids #3DModeling #ResearchInnovation #EthicalResearch #SMM #MarketingStrategy
-
Orientation for Spanios Team at Portal Innovations #bhuvanesh Dave # preethi samuel # Spanios # portal innovation
-
-
Spanios转发了
We’re excited to share our case study for Spanios! Our concept aimed to create the feeling of looking inside a well filled with cells and tumoroids. This work highlights key physiological mechanisms, contributing to ethical research in immuno-oncology. In addition to developing fully animated models of tumoroids, we also designed artwork for their exhibition booth at a conference in San Diego. Check out the full case study for more details, and reach out if you need our expert assistance on your project! https://lnkd.in/gfrYX9Yk #ImmunoOncology #Tumoroids #3DModeling #ResearchInnovation #EthicalResearch #SMM #MarketingStrategy
-
We have moved! Portal Innovations Houston at TMC Helix is our new home!! We are open for business and are building partnerships that will accelerate pre-clinical research in the oncological space, with precision. Reach out to us, stop by to say hello, we are here! #patientderievedtumoroids #COMPASS #SPANIOS
-
-
Spanios is pleased to confirm the execution of a co-marketing agreement (the "Agreement") with Inaphaea a UK based high throughput drug screening services using its Patient Derived Cells ("PDC") as a precursor to Spanos's proprietary Patient Derived Tumoroids ("PDT"). Bhuvanesh Dave, PhD, Co-Founder and CEO of Spanios, commented?"The partnership with Inaphaea is a perfect fit for our joint goal of accelerating drug development to bring therapies to patients faster. Combining Inaphaea's higher throughput approach to candidate selection with our versatile three-dimensional PDT drug testing platform, COMPASS (Custom Organoid Modelling Platform for Accurate & Speedy Solutions) which is capable of recapitulating tumor microenvironment (TME) including features of oxygenation and immunocompetence, we can combine the best of both approaches for advancing discovery and development pipeline."
-
Spanios enters into collaboration with Inaphaea to offer our services to a wider client base.
We are pleased to confirm the execution of a co-marketing agreement with US contract research organisation Spanios.? ? This marks Inaphaea's first co-marketing agreement in the US, providing our high-throughput drug screening services with patient-derived cells (PDCs) as an initial step before transitioning to Spanios's proprietary patient-derived tumoroids (PDTs).? ? Mark Eccleston, Director of Inaphaea BioLabs comments: "We are excited to be working with a highly innovative partner like Spanios. Bringing therapies to market faster requires better models for screening drugs to deliver more accurate and translatable results. Inaphaea has focussed on the early stage of this process where, typically, larger numbers of candidates need to be refined for screening in disease relevant models. We can then pass on the best candidates to Spanios for testing in their organoid platform."? ? Read more about the agreement here:?https://lnkd.in/efNMPqN6 ? #PDCs #BioTech #DrugDiscovery #Assays #AssayDevelopment
-
-
Accelerating the development of cancer therapeutics through partnerships.
In order to facilitate our A Round build and the impending expansion of Spanios through its recent and soon-to-be announced partnerships, Dr.Bhuvanesh Dave, Co-Founder & CSO has been elevated into the role of CEO. I want to thank personally Vivek Ravi for his service and support over the last couple of years and wish him well on his new endeavors. Spanios and its incredible team are dedicated to co-developing cures for the most challenging solid cancers, de-risking cancer investments for shareholders, and ensuring that only effective therapeutics make it into the clinic. All patients deserve nothing less. To partner with us on this mission, please reach out to me. (Photo by the National Cancer Institute (NCI))
-